U 74389G

Drug Profile

U 74389G

Latest Information Update: 04 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Humboldt University; Pfizer; St Vincents Hospital, Sydney
  • Class Anti-ischaemics; Antineoplastics; Neuroprotectants
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Reperfusion injury; Septic shock

Most Recent Events

  • 04 Sep 2006 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
  • 04 Sep 2006 Discontinued - Preclinical for Septic shock in Germany (unspecified route)
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top